Brooke Fletcher
Cardiovascular Disease · Stockton, CANPI 1538783519
Payments from drug & device makers
Across 121 payments — averaging $18.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$392
- E.r. Squibb & Sons, L.L.C.$266
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$224
- Boehringer Ingelheim$214
- United Therapeutics Corporation$193
- AstraZeneca$178
- plus $753 from 19 others
What the payments were for
- Food & beverage$2,12195%
- Education$1005%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 26 | $392 |
| E.r. Squibb & Sons, L.L.C. | 17 | $266 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $224 |
| Boehringer Ingelheim | 10 | $214 |
| United Therapeutics Corporation | 9 | $193 |
| AstraZeneca | 7 | $178 |
| Merck | 5 | $97 |
| Johnson & Johnson | 5 | $85 |
| Kestra Medical Technology Services, Inc. | 3 | $73 |
| Bayer | 4 | $72 |
| Abbott | 2 | $50 |
| Lexicon Pharmaceuticals, Inc. | 3 | $50 |
| Scpharmaceuticals Inc. | 2 | $46 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Amarin Pharma, Inc. | 2 | $37 |
| Boston Scientific | 1 | $33 |
| Pfizer | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Amgen | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Heartflow, Inc. | 1 | $16 |
| GSK | 1 | $14 |
How this compares
$2,220 in reported general payments places this provider in the 45th percentile of 2,184 cardiovascular disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 85 | $66,507 |
| Repatha SureclickEvolocumab | 50 | $32,111 |
| Ranolazine ErRanolazine | 27 | $2,662 |
| Metoprolol Succinate | 121 | $1,284 |
| Atorvastatin Calcium | 178 | $1,167 |
| Ezetimibe | 55 | $1,085 |
| Nebivolol Hcl | 11 | $1,052 |
| Rosuvastatin Calcium | 14 | $676 |
| Carvedilol | 62 | $403 |
| Amlodipine Besylate | 87 | $370 |
| Amiodarone Hcl | 26 | $145 |
| Losartan Potassium | 30 | $141 |
| Furosemide | 48 | $134 |
| ClopidogrelClopidogrel Bisulfate | 14 | $111 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 24 | $101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $25 | $66,50785 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Stockton
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.